Chart: "Behind The Approval Letter: A Year Of Drug Review Profile"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Behind The Approval Letter: A Year Of Drug Review Profiles
You may also be interested in...
Acromegaly Is Poor Setting For Symptom Claim, FDA Somatuline Review Finds
Ipsen could not support extension of acromegaly therapy indications past biochemical endpoints to include clinical symptom claims, according to FDA’s review of the European firm’s Somatuline Depot (lanreotide prolonged-release injection).
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product